Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration
Open Access
- 1 January 2017
- journal article
- research article
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 79 (4) , 788-794
Abstract
Sildenafil is a selective phosphodiesterase-5 inhibitor that has been demonstrated to delay ventricular remodeling in humans and experimental animals. The aim of this prospective study was to assess the chronic effects of sildenafil administration on echocardiographic indices and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in dogs with naturally occurring, asymptomatic myxomatous mitral valve degeneration. Thirty client-owned dogs with ACVIM class B1 or B2 were enrolled. Dogs were randomly assigned to treatment (sildenafil 1-3 mg/kg, PO, BID for 180 days) or control groups. A total of 12 dogs completed the 180 days trial in the sildenafil group, whereas 10 dogs remained in control group. When comparing the difference from baseline values obtained over time between groups, the stroke volume (SV) at day 30 was significantly higher in the sildenafil group (P=0.038). The LA/Ao and the MR jet area were significantly lower beginning at day 30 (only MR jet area; P=0.006), day 90 (P=0.006 and P=0.027, respectively) and day 180 (P=0.029 and P=0.032, respectively). The 2D-LA was significantly lower at day 90 when compared with control group (P=0.028). The differences of NTproBNP from baseline were significantly lower when compared with control group at the same timepoint (D90, P=0.017 and D180, P=0.013). In conclusion, this study suggested that long-term treatment with sildenafil prevented aggravation of disease progression as suggested by several echocardiographic indices (i.e. SV, LA/Ao, MR jet area, 2D-LA) and reduced NTproBNP level at the indicated timepoints in dogs with asymptomatic mitral valve degeneration.Keywords
This publication has 30 references indexed in Scilit:
- Short-Term Effects of Atorvastatin in Normal Dogs and Dogs with Congestive Heart Failure Due to Myxomatous Mitral Valve DiseaseJournal of Veterinary Internal Medicine, 2013
- Increased Cardiac Myocyte PDE5 Levels in Human and Murine Pressure Overload Hypertrophy Contribute to Adverse LV RemodelingPLOS ONE, 2013
- Pharmacologic management of myxomatous mitral valve disease in dogsJournal of Veterinary Cardiology, 2012
- PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart FailureCirculation: Heart Failure, 2011
- An update on treatment and prognostic indicators in canine myxomatous mitral valve diseaseJournal of Small Animal Practice, 2009
- Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibitionJournal of Molecular and Cellular Cardiology, 2009
- Retrospective Evaluation of Sildenafil Citrate as a Therapy for Pulmonary Hypertension in DogsJournal of Veterinary Internal Medicine, 2006
- Retrospective Evaluation of Sildenafil Citrate as a Therapy for Pulmonary Hypertension in DogsJournal of Veterinary Internal Medicine, 2006
- An improved method to correct the QT interval of the electrocardiogram for changes in heart rateJournal of Pharmacological Methods, 1989
- Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.Circulation, 1978